HER2 Testing in Gastric Cancer: A Survival Guide to Interpretation and Application: A Clinical Forum

50-21-416-VL HER2 Web Thumbnail
Proprietary Educational Format:

Activity Overview

In this activity, a panel of experts discuss current methods for determining the HER2 status of gastric adenocarcinomas and/or gastroesophageal junction cancers and the implications of these findings on treatment selection in the first-line setting and beyond.

0.50 CE Credit(s)
Expires: April 1, 2022

Target Audience

Oncology clinicians and other healthcare professionals who diagnose and/or manage patients with gastric cancer.

Learning Objectives

Upon successful completion of this education activity, participants should be better able to:

  • Assess current HER2 testing recommendations and strategies for gastric cancer
  • Apply optimal testing and interpretation strategies to identify patients with gastric cancer that could benefit from HER2-directed therapy
  • Identify current and emerging HER2-directed therapies for gastric cancer

Activity Faculty

Kim, Richard (picture)

Richard Kim, MD (Chair)

Service Chief and Senior Staff, Gastrointestinal Oncology
H. Lee Moffitt Cancer Center
Professor, University of South Florida
Tampa, FL

Catenacci Daniel pic

Daniel Catenacci, MD

Associate Professor, Department of Medicine, Section of Hematology & Oncology
Director, Interdisciplinary Gastrointestinal Oncology Program
Assistant Director, Translational Research, Comprehensive Cancer Center
University of Chicago Medical Center
Chicago, IL

Tang, Laura

Laura H. Tang, MD, PhD

Attending Pathologist
Memorial Sloan Kettering Cancer Center
Professor, Pathology
Will Cornell Medical College
New York, NY